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1. Introduction
The genetic changes that promote progression of prostate adenocarcinomas are multifactori‐
al and include alterations in several genes. The aberrations include those in genes that affect
normal cell adhesion. The long arm of chromosome 16 (16q22.1) is deleted in 30% of primary
prostatic tumors and more than 70% of metastatic prostate cancers. The E-cadherin gene is
located in this region. E-cadherin is involved in maintaining homotypic cell-cell adhesion
between normal prostatic glandular cells. The loss of E-cadherin expression is associated
with metastatic progression of prostate cancer (Mason, 2002). Recent data suggests that ab‐
normal expression of E-cadherin, leading to impaired adhesion, correlates with hematoge‐
nous spread of primary tumor cells in prostate cancer patients (Loric, 2001). The study
further suggests that abnormal E-cadherin expression is a significant independent indicator
of prostate cancer recurrence in patients.
Metastatic dissemination of prostate cancer cells occurs via the lymphatic system as well as
the vascular system. This complex process of metastasis involves a series of steps starting
with neoplastic transformation of prostate cells, tumor angiogenesis/lymphogenesis and
cancer growth, loss of cell adhesion molecules and detachment of cancer cells from primary
tumor, local invasion of stroma, dissemination of primary tumor cells via the lymphatics or
vasculature, avoidance of tumor surveillance by the immune system, homing of primary
prostate cancer cells to distant sites, establishment of tumor and growth of tumor at distant
metastatic site (Arya et al., 2006). While the majority of metastic lesions are found in the ob‐
turator lymph nodes, lesions have also been detected in presacral, presciatic, as well as inter‐
nal and external iliac nodes. Conversely, hematogenous spread of prostate cancer cells
results in the formation of metastatic lesions in the bone, lung, liver and epidural space. In‐
terestingly, in the majority of patients who die from prostate cancer, metastatic lesions have
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been detected in the bone. One study shows that E-cadherin and β-catenin are downregulat‐
ed in prostatic bone metastasis, but not in primary prostate tumors (Arya et al., 2006). The
spine, femur, pelvis, rib cage, skull and humerus are frequent sites of metastatic prostate
cancer lesions. The bone stroma apparently provides a microenvironment suitable for the
growth of metastatic prostate cancer cells. While the molecular mechanisms associated with
prostate cancer metastasis are not completely elucidated, potential markers of high-risk
prostate cancer include the cadherins, catenins, focal adhesin kinase, connexins, integrins
and metalloproteinases (Mol et al., 2007).
The E-cadherin-catenin complex and associated proteins have functional roles in cell-adhe‐
sion as well as in downstream signaling. It is well known that increased expression of cyto‐
plasmic β-catenin is associated with increased translocation to the nucleus leading to
transcriptional activation of β-catenin-TCF responsive genes. β-catenin, γ-catenin and
p120ctn proteins are expressed in the nucleus, thereby suggesting that a complex system of
checks and balances may exist in normal as well as in tumor cells.
2. Classical cadherins, type I
2.1. E-cadherin
The tight association of individual cells at junctional organelles and the polarized distribu‐
tion of cytoplasmic and cell surface-components are the primary characteristics of normal
epithelial tissues. As a result of this adhesion, normal epithelial cells are less mobile as com‐
pared to either cells of mesenchymal origin or to cancer cells of epithelial origin. Normal ep‐
ithelial cells also have the ability to form selective permeability barriers, and to exhibit
vectorial transport in tissues. Four organelles (tight junctions, desmosomes, gap junctions,
zonula adherens junctions) are responsible for adhesion between two adjacent cells. In addi‐
tion, distinct proteins are associated with each of these types of intracellular junctions, sug‐
gesting a specific role of each junction in normal cellular processes. First are the tight
junctions, which have dual functions: maintenance of cell polarity and inhibition of uncon‐
trolled exchange of small molecules, macromolecules, and water between two adjacent cells.
Occludin and ZO-1 protein complexes are typically found in tight junctions in epithelial and
endothelial cells (Schnittler et al., 1998). Second, desmosomes typify cells that have under‐
gone epithelial differentiation. Desmosomes function in homophilic adhesion between adja‐
cent cells and link desmosomal proteins to the cytoskeletal proteins called intermediate-
sized filaments (Ifs). Desmoglein and desmocollin are pivotal components of desmosomal
function (Schafer et al., 1996; Mertens et al., 1999). Third, gap junctions form intracellular
channels that allow direct transfer of ions and metabolites. Connexin proteins form these
gap junction channels (Dermietzel and Hofstadter, 1998; Windoffer et al., 2000). Zonula ad‐
herens junctions, the fourth type of organelles, are specialized structures containing the cell
adhesion molecule E-cadherin.
The human E-cadherin gene, CDH1, is located on chromosome 16q22.1 (Rimm et al., 1994).
It encodes a 135 kDa precursor form of E-cadherin. In essence, the precursor form cannot
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function in homophilic adhesion without undergoing N-terminal cleavage. The precursor E-
cadherin protein is cleaved in the cytoplasm to form a mature 120 kDa protein containing
the newly formed extracellular N-terminal domain. The extracellular domain or N-terminal
end of E-cadherin is essential for homophilic calcium-dependent cell-cell adhesion. The ma‐
ture form of E-cadherin, on the other hand, is transported to the basolateral surface of the
epithelial cell where it can function in homophilic adhesion.
The mature E-cadherin contains three distinct domains: the highly conserved carboxy-termi‐
nal domain, a single pass transmembrane domain, and an extracellular domain (Figure 1).
The extracellular domain consists of five tandem subdomain repeats that bind calcium, re‐
ferred to as C1-C5 subdomains with the C1 domain being the most distal from the cell mem‐
brane. The C1 subdomain contains a histidine-alanine-valine sequence (HAV) that is
speculated to be essential for the process of cell-cell adhesion. E-cadherin exists as a cis dim‐
er on an individual cell when it is not adhering to an adjacent cell. Subsequent to calcium
binding, a conformational change occurs in the HAV structure of the C1 subdomain, allow‐
ing the tryptophan-2 residue to move into a hydrophobic cavity. This conformational
change allows E-cadherin to form a trans dimer ‘zipper’ between two adjacent cells. Subse‐
quent linkage to the cytoskeleton stabilizes cell-cell adhesion. The cytoplasmic domain of E-
cadherin is required for cadherin-catenin complex formation. The cytoplasmic tail of E-
cadherin consists of two regions: the juxtamembrane region and the catenin-binding region.
These regions are principally required for clustering of E-cadherin at cell-cell contacts (juxta‐
membrane) and as a major link to the actin cytoskeleton. These regions are known to stabi‐
lize E-cadherin clusters and participate in signal transduction processes via the catenin-
binding region. The thirty-two amino acid, hydrophobic transmembrane region separates
the extracellular domain from the highly conserved intracellular domain.
E-cadherin forms a complex with four catenin proteins, α-catenin (102 kDa), β-catenin (92
kDa), γ-catenin (83 kDa) and p120 catenin (75-120 kDa). The interaction of E-cadherin with
cytoplasmic catenins, α, β, γ and p120 (p120ctn) is required for the normal function of E-cad‐
herin. The human genes for all four cadherin-associated catenins have been cloned and char‐
acterized; the genes are located on four different chromosomes. While α-Catenin is located
on chromosome 5q31, β-catenin is located on chromosome 3p21, γ-catenin on chromosome
17q21, and p120ctn on chromosome 11q11 immediately adjacent to the centromere. All four
catenins bind to E-cadherin, but exist as two distinct pools of E-cadherin-catenin complexes
in the same cell. E-cadherin binds to either β-catenin or γ-catenin, but does not directly bind
to α-catenin. α-catenin, however, binds to either β-catenin or γ-catenin. Therefore, in a sin‐
gle cell, one complex consists of E-cadherin with α− and β-catenin, and the other complex
consists of E-cadherin with α and γ-catenin. E-cadherin-catenin complex formation begins
shortly after biosynthesis, while still in the endoplasmic reticulum. The sequential order of
cadherin-catenin complex formation begins with β-catenin interacting with E-cadherin. If E-
cadherin fails to associate with β-catenin, E-cadherin is retained in the endoplasmic reticu‐
lum where it is subsequently degraded. A 30 amino-acid region within the cytoplasmic
domain of E-cadherin is essential for β-catenin binding. E-cadherin and β-catenin are trans‐
ported together in a bipartite fashion to the cell surface, where they associate with α-catenin.
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The amino-terminal region of α-catenin binds to actin filaments in the cytoplasm, linking the
cadherin-catenin complex to the cytoskeleton. Post-translational modification of p120ctn is as‐
sociated with modulation of cadherin clustering and stablization of adhesion.In summary, a
functional cadherin-catenin complex is important for maintaining cellular integrity.
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Figure 1. Schematic diagram of E-cadherin-catenin complex. The mature E-cadherin contains three distinct do‐
mains: the highly conserved cytoplasmic domain, a single pass transmembrane domain (TM), and an extracellular do‐
main. The cytoplasmic tail of E-cadherin consists of two regions: the juxtamembrane domain (JMD) and the catenin-
binding domain (CBD). β- and γ-Catenin bind to the CBD, and p120ctn binds to the JMD regions of E-cadherin. These
regions are principally required for clustering of E-cadherin at cell-cell contact and as a major link to the actin cytoske‐
leton. E-cadherin forms a complex with four catenin proteins, α-catenin (102 kDa), β-catenin (92 kDa), γ-catenin (83
kDa), and p120 catenin (75-120 kDa). α, α-catenin; β, β-catenin; γ, γ-catenin; p120ctn, p120 catenin.
2.2. Role of Cadherin in physiological and pathological processes
E-cadherin expression is regulated in both physiological and pathological processes, such as
embryonic morphogenesis and tumorigenesis. Tissue and organ formation is regulated in a
spatio-temporal manner involving cell proliferation, death, cell-cell adhesion, cell-substrate
adhesion, polarization, and migration. One example of this highly regulated process is blas‐
tocyst differentiation. E-Cadherin has an essential function in the formation of the blastocyst
during mouse embryonic development. Another example of the normal physiological proc‐
esses associated with E-cadherin regulation is the formation of fluid space in development
of murine cochlea. In this embryonic process, E-cadherin is downregulated on the lateral
membranes of reticular lamina. This down-regulation allows the process of fluid space
opening in the organ of Corti. Wound healing is a third example where a physiological
event involves regulation of E-cadherin expression. Injury of the epithelial cell layer in the
skin signals the release of cytokines and other factors, such as epidermal growth factor
(EGF). These signals reduce cell adhesion and stimulate cell motility, allowing for wound re‐
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pair. Subsequent to wound repair, cell adhesion is upregulated to restore the epithelial layer
to its normal physiological state. Therefore, E-cadherin has to be highly regulated in the
above normal physiological processes. Conversely, aberrant growth and differentiation re‐
sult when E-cadherin is not tightly regulated, such as in cancer.
Association of E-cadherin with neighboring cells acts to inhibit cell mobility and to main‐
tain normal epithelial cell phenotype. Tumorigenesis is an example of a pathological proc‐
ess  that  involves  E-cadherin  regulation.  The  loss  or  down-regulation  of  E-cadherin
expression has been described in several tumors including stomach (Shino 1995; Tamura,
2000), colon (Van Aken, 1993; Dorudi, 1993), pancreas (Pignatelli,  1994), liver (Joo, 2002),
prostate (Morton et al., 1993; Umbas et al., 1994; Ross et al., 1994; Bussemakers et al, 1994;
Pan et al., 1998; Noe et al., 1999; Cheng et al., 1996), breast (Lim and Lee, 2002; Hiraguri et
al, 1998; Moll et al., 1993; Palacios et al., 1995; Gamallo et al., 1993; Oka et al., 1993; Ras‐
bridge et al., 1993; De Leeuw et al., 1997), uterus (Sakuragi et al., 1994), ovary (Veatch et
al., 1994), thyroid (Brabant et al., 1993), and head and neck (Mattijssen et al., 1993). Recent
reports suggest that poorly differentiated tumors exhibit reduced E-cadherin expression as
a  consequence  of  down-regulation  or  defects  in  catenins  (Kadowaki  et  al.,  1994;  Kawa‐
nishi  et  al.,  1995;  Navarro  et  al.,  1993;  Oyama et  al.,  1994).  Therefore,  the  results  from
these studies suggest that the degree of differentiation of tumors is related to the level of
E-cadherin expression.
E-cadherin acts as an inhibitor of the invasive and metastatic phenotype of cancer cells.
Since tumor invasion and metastasis is a multistep process, E-caderin may play a significant
role in regulating invasion and metastasis at the initial steps in the process by promoting ho‐
motypic cell-cell adhesion. Numerous mechanisms affecting E-cadheirn-catenin complex
formation are associated with a reduction in cell adhesion. While gene mutation is responsi‐
ble for inactivating E-cadherin-mediated cell adhesion in some breast cancers and gastric ad‐
enocarcinomas (Berx et al., 1998a; Berx et al., 1998b), the exact mechanism of E-cadherin
down-regulation in other highly invasive tumors is still under investigation. Mechanisms
that regulate homophilic cell adhesion include reduction or loss of E-cadherin expression,
reduced transcription of genes encoding catenin proteins, redistribution of E-cadherin to dif‐
ferent sites within the cell, shedding of E-cadherin, cleavage of E-cadherin, and competition
of proteins for binding sites on E-cadherin (Cavallaro and Christofori, 2004).
The proximal E-cadherin promoter contains multiple regulatory elements including three
E-boxes, a single CCAAT box, and a GC-rich element. Therefore, the E-cadherin promoter
contains more than one site for transcription factors to bind and regulate gene transcrip‐
tion  in  cancers.  These  factors  include  AP-2  (Batsche  et  al.,  1998),  SNAIL  (Battle  et  al.,
2000),  SLUG (Hajra  et  al.,  2002),  dEF1/ZEB-1 (Grooteclaes  and Frisch,  2000),  SIP1/ZEB-2
(Comijn  et  al.,  2001),  E12/E47  (Perez-Moreno  et  al.,  2001),  and  LEF/TCF  (Huber  et  al.,
1996). While the retinoblastoma gene and c-myc protooncogene products transactivate the
E-cadherin promoter in epithelial cells through interaction with AP-2 transcription factors
(Batsche et al.,  1998), transcription of E-cadherin is down-regulated by overexpression of
ErbB2 (D’Souza and Taylor-Papadimitriou, 1994).  SNAIL and SLUG transcription factors
have been shown to repress E-cadherin expression in breast cancer cell lines via all three
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E-box elements, but particularly, via EboxA and EboxC, located in the proximal E-cadher‐
in promoter (Hajra et al., 2002). Moreover, SLUG is a putative in vivo repressor of E-cad‐
herin in breast cancer (Hajra et al., 2002). The E-cadherin promoter also contains binding
sites for the lymphoid enhancer factor 1 (LEF1)-β-catenin transcription factor complex; this
complex down-regulates E-cadherin expression (Huber et al., 1998). Overexpression of in‐
tegrin-linked protein kinase (p59ilk) stimulates LEF1-β-catenin signaling and causes down‐
regulation of E-cadherin expression with a concomitant decrease in cell adhesion (Novak
et al., 1998). A single nucleotide polymorphism in the E-cadherin promoter has also been
associated with a higher risk of prostate cancer in certain ethnic populations with a possi‐
ble  role  in  transcriptional  regulation of  E-cadherin  gene expression in  these  individuals
(Goto et al., 2007).
Gene  transcription  can  also  be  regulated  by  epigenetic  inactivation.  Many  cancer  cells
have been shown to use this mechanism to inactivate tumor-suppressor genes (Sidransky,
2002).  Methylation  of  genes  that  encode  p16  (cyclin-dependent  kinase  inhibitor),  DAPK
(death-associated protein kinase, apoptosis associated protein), and MGMT (a DNA repair
protein, methyl O-guanine methyltransferase) has been implicated in lung, and head and
neck cancer (Esteller et al.,  1999; Sanchez-Cespedes et al.,  2000). Aberrant methylation of
the hMLH1 promoter has also been associated with microsatellite instability in colon can‐
cer  (Grady et  al.,  2001).  Methylation  of  APC (Usadel  et  al.,  2002),  a  key  component  in
Wnt-β-catenin signaling, is associated with early-stage lung cancer and esophageal cancer
(Kawakami, 2000). E-cadherin expression is downregulated in highly invasive prostate tu‐
mors as a result of transcriptional regulation (Morton et al., 1993; Kuczyk et al, 1998). Re‐
duction  in  E-cadherin  expression  in  prostate  cancer  cells  has  been  attributed  to
hypermethylation  of  CpG  islands  in  the  E-cadherin  gene  promoter  (Graff  et  al.,  1995;
Graff et al., 1997; Herman et al., 1996; Hirohashi, 1998; Li et al., 2001). This type of silenc‐
ing  of  E-cadherin  gene  expression  is  also  seen  in  cervical  cancer  cell  lines  and  tumors
(Chen et al., 2003). In summary, epigenetic inactivation of genes is an alternative mecha‐
nism  used  to  regulate  expression  of  certain  genes  in  cancer  cells.  The  significance  and
mechanism of gene inactivations associated with prostate cancer cell  invasion remain to
be determined.
Post-translational  modification  is  an  alternative  mechanism  to  regulate  E-cadherin-de‐
pendent homophilic cell  adhesion (Hirohashi,  1998).  Protein tyrosine kinases (PTKs) and
phosphatases (PTPs), regulate intracellular phosphotyrosine levels, thereby regulating di‐
verse  cellular  behaviors  such  as  adhesion,  growth  and  differentiation,  and  migration.
Her2/Neu or ErbB2 tyrosine kinase, as well as transmembrane tyrosine phosphatases such
as PTPμ, PTPκ, PTPλ and LAR, have been found to be associated with cadherin-catenin
complexes  in  epithelial  cells,  suggesting  opposing  roles  for  these  proteins  in  regulating
cadherin-catenin association (Hellberg et al., 2002). Stimulation of growth factor receptors,
i.e. EGF receptor (EGFR), can also regulate E-cadherin expression in tumor cells in a post-
translational manner (Hazan and Norton, 1998; Moustafa et al, 1999). A reciprocal and re‐
versible  control  of  intercellular  adhesion  and  cell  proliferation  occurs  with  increased
expression of EGFR in several epithelial tumors (Jawhari et al, 1999). Restoration of E-cad‐
Advances in Prostate Cancer646
herin expression in human papilloma virus-transfected keratinocytes reversed the invasive
phenotype and, interestingly, down-regulated EGFR expression (Wilding et al., 1996). An
inverse  relationship  between  EGFR  activation  and  E-cadherin  expression  was  also  ob‐
served in lung cancer cells treated with neutralizing monoclonal antibody to EGFR (Mous‐
tafa et al., 1999). By blocking EGFR stimulation in lung cancer cells, E-cadherin expression
is induced. Activation of Src can also induce tyrosine phosphorylation of E-cadherin and
inhibit cell-cell adhesion. As a result of Src activation, the E-cadherin complex is ubiquiti‐
nated, leading to its endocytosis and thereby inhibiting homophilic cell adhesion (Fujita et
al.,  2002).  Either transcriptional or post-translational modification of the cadherin-catenin
complex can determine the integrity of the adherens junction, as well as regulating down‐
stream signaling.
3. E-cadherin associated catenin proteins
3.1. α-catenin
The α-catenin gene encodes a 102kDa protein that links E-cadherin to the actin cytoskeleton.
The amino terminus of α-catenin contains the actin-binding domain essential for linking the
cadherin-catenin complex to the cytoskeleton (Beavon, 2000). The cytoplasmic components
of the adherens junctions are necessary for linking cadherins to actin (Takeichi, 1991). The
association of cadherins with the cytoskeleton is mediated via either α-actinin (Nieset et al.,
1997; Knudsen et al., 1995) or vinculin (Hazan et al., 1997a; Weiss et al., 1998; Watabe-Uchi‐
da, 1998). α-Catenin is also known to interact with ZO-1 (Itoh et al., 1997). α-catenin asso‐
ciates with either β-catenin or γ-catenin in adherens junctions, but does not form a complex
in desmosomes where γ-catenin is bound to desmosomal cadherins and desmoplakin, an‐
other desmosomal protein. Therefore, α-catenin links E-cadherin-catenin proteins to the cy‐
toskeleton at adherens junctions, but not at desmosomes. This would suggest that α-cateinin
may contribute to the stability of the E-cadherin-catenin complex in normal tissues. Recent
studies have suggested that α-catenin is the best prognostic marker for prostate cancer spe‐
cific survival (van Oort et al., 2007).
3.2. β-catenin
β-catenin is a 92 kDa multifunctional protein that belongs to the armadillo family of pro‐
teins, characterized by a central domain of 12 repeats of about 40 amino acids called arm re‐
peats (Figure 2). The arm domain was originally described in armadillo, which is the
Drosophila homologue of β-catenin (Kodama et al., 1999). β-catenin serves as a link between
cadherins and the actin cytoskeleton. β-catenin also binds to numerous other proteins in
cadherin-independent complexes (Behrens, 2002) such as APC, lymphoid enhancer factor
and T-cell factor (LEF/TCF) transcription factors, RGS domain proteins axin/conductin (Ki‐
kuchi, 1999; Kikuchi, 2000; Von Kries et al., 2000; Akiyama, 2000) and prontin 52 (Bauer et al,
1998). β-catenin also associates with fascin, an actin-binding protein, in a cadherin inde‐
pendent manner (Tao et al., 1996).
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Figure 2. Diagram of the twelve armadillo repeats of β-catenin. The β-catenin protein consists of 12 armadillo re‐
peats designated as 1-12. β-Catenin associates with specific proteins within the indicated region of the 12 repeats, in a
mutually exclusive manner. Armadillo repeats 1-7 is designated as the LEF binding region; E-cadherin binds to repeats
4-12; APC binds to repeats 1-10; Tcf binds to repeats 3-8 of the β-catenin protein. Armadillo protein 12 has been
shown to be involved in transactivation of Wnt-responsive genes. N, N-terminus; C, Carboxy-terminus; LEF, lymphoid
enhancer-binding factor ; APC, adenomatous polyposis coli; TCF, T-cell Transcription factor.
In addition to its role in cell-adhesion, β-catenin is associated with Wnt signal transduction
pathway (Figure 3). This pathway is important in regulating embryonic development, and
generation of cell polarity. Wnt proteins are differentially expressed in tissues during mam‐
malian development (Cadigan and Nusse, 1997). These proteins are particularly important
in regulating tissue differentiation and organogenesis (Behrens, 2002; Parr and McMahon,
1994; Willert and Nusse, 1998; Brown and Moon, 1998; Bullions and Levine, 1998). When
Wnt proteins are aberrantly activated, tumor formation ensues (Moon and Kimelman, 1998;
Zeng et al., 1997; Wodarz and Nusse, 1998; Peifer and Polakis, 2000; Bienz and Clevers, 2000;
Barker and Clevers, 2000). Wnt has also been demonstrated to play a role in cancer develop‐
ment by transmitting a signal via its cytoplasmic component, β-catenin protein (Lejeune et
al., 1995; Shimizu et al., 1997; Polakis, 2001; Polakis, 2000; Polakis 1999; Eastman and Gros‐
schedl, 1999; Cadigan and Nusse, 1997). Recent studies have suggested that Wnt proteins
may have a role in tumor-induced osteoblastic activity, which is characterized by increased
bone production as a result of prostate caner metastasis to the bone (Hall et al., 2006). Wnt
proteins bind to cell surface receptors termed Frizzled (Fz). This interaction results in the ac‐
tivation of the cytoplasmic phosphoprotein disheveled (Dvl). Activated Dvl inhibits activa‐
tion of axin and conductin proteins in the Wnt signaling cascade. Axin and its homolog,
conductin (Axin2/Axil) form a multiprotein complex with APC and GSK3β; this activated
complex catalyzes the phoshphorylation of β-catenin at specific residues in its N-terminal
domain (Behrens, 2002; Ikeda et al., 1998). Axin and conductin act as scaffold proteins that
directly bind several components of the Wnt signaling pathway, promoting the phosphory‐
lation of β-catenin by GSK-3β (Jho et al., 2002; Ikeda et al., 1998; Fagotto et al., 1999; Itoh et
al., 1998; Hsu et al., 1999; Julius et al., 2000). Four ser/thr residues in the N-terminal region of
β-catenin are targets for GSK-3β phosphorylation. In the absence of a Wnt signal, GSK3β
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phosphorylates β-catenin, which is then targeted for ubiquitination and subsequently de‐
graded by proteasomes. Interestingly, recent studies show that additional proteins are in‐
volved in priming β-catenin for phosphorylation by GSK3β. Casein kinase I, Casein kinase II
and GSK3β act together in marking β-catenin for phosphorylation (Polakis, 2002; Amit et al.,
2002; Liu et al., 2002; Yanagawa e al., 2002; Zhang et al., 2002).
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Figure 3. Diagram of Wnt signaling pathway. This schematic represents the Wnt-mediated signaling pathway that
functions to stabilize cytoplasmic β-catenin. In the absence of Wnt signaling, β-catenin is degraded by the activity of
glycogen synthase kinase 3β (GSK3β) in a complex with APC, axin, axin2 (conductin/Axil), and β-TrCP. The binding of
Wnt proteins to its receptor, Frizzled (Fz) at the cell surface leads to the activation of Disheveled (Dvl) in the cytoplasm.
Subsequently, GSK3β complex is inactivated and β-catenin accumulates in the cytoplasm, then enters the nucleus to
interact with LEF/TCF proteins. β-Catenin-Tcf transcription factor activates the expression of Wnt responsive genes.
Regulation of β-catenin degradation is pivotal in downstream signaling. Several gene mu‐
tations  have  been reported in  human cancers  that  render  β-catenin  resistant  to  GSK-3β
mediated degradation. First, mutations in APC, a suppressor in human cancers, are associ‐
ated with aberrant expression of β-catenin in colon cancers (Kawahara et al., 2000; Bienz
and Clevers, 2000; Polakis 2000; Bright-Thomas and Hargest, 2002; Kawasaki et al., 2003).
Second, oncogenic mutations have been identified in β-catenin at putative GSK-3β phos‐
phorylation sites, which stabilize β-catenin in colorectal cancer and melanoma (Van Noort
et al., 2002, Morin et al., 1997 and Korinek et al., 1997). Third, a mutation in human AX‐
IN1 has  been found to  be  associated with hepatocellular  carcinoma (Satoh et  al.,  2000),
while a mutation in AXIN2 (also called conductin) is found in colorectal and liver cancers
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(Liu et al., 2000; Lustig et al., 2002). Conversely, constitutive Wnt signaling negatively reg‐
ulates the ubiquitination and degradation of cytosolic β-catenin leading to its stabilization.
In  summary,  stabilization  of  β-catenin  in  the  cytosol  is  altered  by  three  independent
mechanisms: 1) gene mutation of any one of the degradation complex components: APC,
axin, axin2 or GSK-3β, 2) gene mutation of β-catenin, or 3) constitutive Wnt signaling. As
a  result,  the  level  of  cytosolic  β-catenin  increases,  and β-catenin  translocates  to  the  nu‐
cleus where it interacts with transcription factors of the LEF/TCF family. Several negative
feedback loops could limit the duration or intensity of a Wnt-initiated signal. First, the F-
box protein β-TrCP is an ubiquitin-ligase complex that has been shown to be involved in
the proteasome mediated degradation of phosphorylated β-catenin (Chen et al., 1997; Beh‐
rens, 2002; Winston et al., 1999, Hart et al., 1999; Latres et al., 1999; Kitagawa et al., 1999).
β-TrCP is  post-transcriptionally  induced by  β-catenin/TCF signaling.  As  a  result  of  this
signal,  β-catenin  degradation  is  accelerated.  Second,  Tcf4/β-catenin  signaling  regulates
transcription  of  the  Tcf1  gene  in  epithelial  cells.  While  TCF1  does  not  bind  β-catenin,
TCF1  binds  to  transcriptional  repressors  such  as  groucho,  which  would  allow TCF1  to
serve  as  a  feedback repressor  of  β-catenin/Tcf4  target  genes  (Roose  et  al.,  1999;  Polakis
2002). Third, axin2 (conductin) appears to downregulate β-catenin to normal levels after a
Wnt signal in a negative feedback loop mechanism (Jho et al.,  2002;  Leung et al.,  2002).
This would suggest that, without precise regulation of Wnt-initiated signaling, β-catenin is
aberrantly expressed.  As a  result,  downstream target  genes that  might  contribute to  tu‐
morigenesis are either up- or downregulated.
Increased concentration of  β-catenin  in  the  cytoplasm promotes  its  binding to  LEF/TCF
family of DNA-binding proteins. As a result, β-catenin translocates to the nucleus where
it transcriptionally activates specific target genes. Although the exact mechanism of nucle‐
ar translocation of β-catenin has not been elucidated, association of β-catenin with several
nuclear transport proteins, including importin/karyopherin and Ran (Wiechens and Fagot‐
to, 2001; Fagotto et al., 1998), is not responsible. β-catenin lacks a classical nuclear localiza‐
tion  sequence,  but  the  armadillo  repeats  at  the  C-terminus  are  essential  for  nuclear
translocation (Figure 2; Giannini et al.,  2000; Funayama et al.,  1995). Recent studies have
suggested that, in prostate cancer cells, β-catenin can translocate into the nucleus as part
of a complex with androgen receptor, AR, (Mulholland et al., 2002). This association of β-
catenin with the androgen receptor is abrogated in the absence of armadillo repeat 6, fur‐
ther  supporting  the  association  of  certain  armadillo  repeats  with  specific  β-catenin
functions. Armadillo repeats 4-12 are required for β-catenin to bind to E-cadherin (Hulsk‐
en et al., 1994; Orsulic 1996; Piedra et al., 2001). The expression of cadherin proteins could
thus  sequester  β-catenin  to  the  plasma  membrane,  preventing  its  nuclear  translocation
(Heasman et al., 1994; Fagotto et al., 1996; Weng et al., 2002). In the absence of sequester‐
ing proteins,  β-catenin co-localizes with LEF/TCF in the nucleus to transactivate specific
genes that contain LEF/TCF binding sites.
LEF-1 and TCF1-4 were first  identified in  immune cells  (Clevers  and van De Wetering,
1997).  LEF-1  is  a  sequence-specific  DNA-binding protein  that  is  expressed in  pre-B and
pre-T  lymphocytes  of  adult  mice  as  well  as  in  the  neural  crest,  mesencephalon,  tooth
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germs and whisker follicles (Van Genderen et al., 1994). In addition to its role in organo‐
genesis  and  embryogenesis,  constitutive  LEF/TCF/β-catenin  transactivation  is  associated
with oncogenesis in human colon carcinomas and melanomas (Korinek et al., 1997; Morin
et al., 1997; Rubinfeld et al., 1997; Aoki et al., 1999). Although LEF/TCFs can bind directly
to DNA through their HMG or DNA-binding domain, they are incapable of independent‐
ly  activating  gene  transcription  (Polakis  2000;  Polakis  2002,  Behrens,  2002;  Jiang  and
Struhl,1998;  Kiatagawa  et  al.,  1999;  Hecht  et  al.,  1999;  Eastman  and  Grosschedl,  1999;
Roose et al., 1999). Specific regions of β-catenin are required to interact with either LEF or
TCF proteins.  Armadillo  repeats  1-7  of  β-catenin  interact  with  LEF  while  armadillo  re‐
peats 3-8 interact with TCF (Fig 1-3; Piedra et al.,  2001; Sadot 1998; Behrens et al.,  1996;
Van de Wetering, 1997). β-catenin forms a complex with LEF/TCF proteins, depending on
the amount of free β-catenin available. In this complex, LEF/TCF provides the DNA bind‐
ing domain while β-catenin provides the transactivation domain. β-catenin binds specifi‐
cally  to  sequences  1-51  of  Tcf-4  (Miravet  et  al.,  2002).  Activation  of  this  transcriptional
complex between β-catenin and Tcf induces the expression of specific target genes (Miz‐
ushima et al., 2002; Behrens, 2002; Polakis 2002). Examples of these genes include ultrabi‐
thorax  in  Drosophila,  nodal  related  3  (McKendry  et  al.,  1997),  and  siamois  in  Xenopus
(Brannon et al., 1997), and c-myc (He 1998; Kolligs et al., 2000) and cyclin D1 (Tetsu and
McCormick, 1999; Shtutman et al., 1999) in mammals. The list of target genes also include
genes that regulate cellular functions other than stimulating cell growth, such as cyclooxy‐
genase-2 (Howe et al., 2001); multi-drug resistance gene (Yamada et al., 2000); AF17 (Lin
et al., 2001); metalloproteinase 7 (MMP-7) (Crawford et al., 1999; Brabletz et al., 1999); per‐
oxisome  proliferator-activated  receptor  δ  (He  1999);  laminin-5  γ2  (Hlubek  2001);  c-jun/
fra-1 (Mann et  al.,  1999)  TCF-1 (Roose et  al.,  1999);  axin2 (Jho et  al.,  2002;  Leung et  al.,
2002); ITF-2 (Kolligs et al.,  2002); E-cadherin (Huber et al.,  1998; Novak et al.,  1998); and
mesenchymal genes (Huber et al., 1996; Miller and Moon, 1996; Novak and Dedhar, 1999).
3.3. Post-translational modification of β-catenin
The armadillo repeat domains of β-catenin are essential for binding to its many partners
including E-cadherin, α-catenin and TCF-4. This association of β-catenin with various pro‐
teins  is  regulated  by  post-translational  modification  at  specific  sites  of  the  arm  repeats
(Piedra et al., 2001). Sequences in central arm repeats 4-12 are required for β-catenin to as‐
sociate with E-cadherin (Hulsken et al., 1994). Moreover, phosphorylation of tyrosine resi‐
due  654  (located  in  arm  repeat  12)  decreases  association  of  β-catenin  with  E-cadherin
(Roura et  al.,  1999).  Simultaneously,  phosphorylation of  tyr-654 stimulates binding of β-
catenin to the basal transcription factor TATA-binding protein (TBP). Phosphorylation of
tyr-654 removes steric hindrance at the C-terminal allowing better access of key compo‐
nents of the transcriptional machinery, such as TBP. Since Tcf-4 binds to armadillo repeats
3-8,  its  association with β-catenin is  not  affected by phosphorylation of  tyr-654 (arm re‐
peat 12). β-Catenin binding to α-catenin is determined by a short 31 amino-acid sequence
in the first armadillo repeat of β-catenin (Aberle et al., 1994). However, this association be‐
tween β- and α-catenin is not affected by any known post-translational modifications of
tyrosine residues.
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3.4. γ-catenin
γ-Catenin and β-catenin are closely related and are members of the gene family that in‐
cludes the Drosophila protein armadillo (Kodama et al., 1999; McCrea et al., 1991). γ-Cat‐
enin  is  identical  to  plakoglobin  (Peifer  et  al.,  1992;  Knudsen  and  Wheelock,  1992).  γ-
Catenin  and  β-catenin  share  80%  sequence  identity  in  the  twelve  arm  repeat  domains
(Huber and Weis, 2001), but only share 29% and 41% sequence identity in the N- and C-
terminal  regions,  respectively.  There  are  two types  of  cell-cell  junctions:  adherens  junc‐
tions  and  desmosomes  (Takeichi,  1991;  Cowin  and  Burke,  1996).  While  adherens
junctions have one transmembrane component, E-cadherin, desmosomes have two trans‐
membrane components,  desmoglein and desmocollin  (Buxton et  al.,  1993).  Similar  to  β-
catenin,  γ-catenin  binds  directly  to  E-cadherin  and  α-catenin  at  adherens  junctions
(Aberle et  al.,  1994;  Hulsken et  al.,  1994).  γ-Catenin is  the only component of  both des‐
mosome and adherens junctions,  suggesting a pivotal  role in cell-cell  adhesion. In addi‐
tion  to  forming  a  complex  with  E-cadherin,  γ-catenin  interacts  with  the  cytoplasmic
regions  of  desmoglein  and  desmocolin  (Kowalczyk  et  al.,  1994;  Mathur  et  al.,  1994;
Troyanovsky  et  al.,  1994a;  Troyanovsky  et  al.,  1994b;  Wahl  et  al.,  1996;  Witcher  et  al.,
1996).  Arm repeats 1-4 of  γ-catenin specifically interact  with desmoglein.  In contrast,  γ-
catenin  arm  repeats  11-12  are  required  for  binding  desmocolins,  but  not  desmogleins
(Witcher et al., 1996). A recent model proposes that the amino- and carboxy-terminal do‐
mains  of  γ-catenin  form intramolecular  interactions  with  the  armadillo  domain,  inhibit‐
ing  its  association  with  desmoglein  (Wahl,  2000).  Classical  cadherins,  which  include  E-
and N-cadherin,  bind to the same site on γ-catenin as desmocolin (Hulsken et al.,  1994;
Sacco et  al.,  1995).  Therefore,  complexes  consisting of  E-cadherin,  γ-  and α-catenins  are
formed  at  adherens  junctions,  while  γ-catenin,  desmoglein  and  desmocolin  complexes
are formed at desmosomes in a mutually exclusive manner. γ-Catenin in adherens junc‐
tions and desmosomes may have a potential  role in organizing cadherins into an adhe‐
sive  zipper  between  two adjacent  cells,  thereby  tightening  the  association  between  two
cells. γ-Catenin is also found in the cytoplasm, where it forms a homodimer of unknown
function (Cowin et al., 1986). The α-catenin binding region maps to the first repeat of γ-
catenin,  while  N-cadherin  binding  region  maps  within  repeats  7  and  8  (Sacco  et  al.,
1995).  γ-Catenin, like β-catenin (Ben Ze’ev and Geiger,  1998),  interacts with several pro‐
teins, such as classical cadherins (Sacco et al., 1995), α-catenin (Nieset et al., 1997), fascin
(Tao et al., 1996), axin (Ikeda et al., 1998; Behrens et al., 1998; Hart et al., 1999; Itoh et al.,
1998), APC (Hulsken et al., 1994), and LEF/TCF transcription factors (Simcha et al., 1998;
Huber et al., 1996). Tcf-4, however, contains two different sites for binding β- and γ-cate‐
nin. Interaction with γ-catenin inhibits transcription of downstream target genes (Miravet
et al., 2002). β-Catenin binds to amino acids 1-50 of Tcf-4, whereas γ-catenin binds to res‐
idues  51-80.  Tcf-4  specifically  binds  to  γ-catenin  in  the  region  of  arm repeats  1-6.  Fur‐
thermore, in vitro  kinase assays have suggested that phosphorylation of Tcf-4 negatively
affects  its  interaction  with  γ-catenin  without  altering  its  association  with  β-catenin.
Therefore,  γ-catenin can contribute to homophilic  cell-adhesion involving both adherens
junctions and zonula adherens junctions.
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3.5. p120ctn
p120Catenin (p120ctn) was originally described as a tyrosine-phosphorylated protein in Src-
transformed cells (Reynolds et al., 1992; Peifer et al., 1994; Mariner et al., 2000; Noren et al.,
2000). Recent evidence suggests pleiotropic functions of p120ctn such as cadherin clustering
(Yap, 1998a; Yap et al., 1998b), cell motility (Chen et al., 1997), cadherin turnover at the cell
surface (Davis et al., 2004), as well as regulation of neuronal outgrowth and of cadherin-cat‐
enin complex stability (Aono et al., 1999; Ohkubo and Ozawa, 1999). While α-, β- and γ-cate‐
nins bind to the catenin-binding domain (CBD) of the cadherin cytoplasmic tail, p120ctn
binds to the juxtamembrane domain (JMD). Unlike the other catenin proteins, p120ctndoes
not interact with α-catenin, APC, or transcription factor Lef-1 (Daniel and Reynolds, 1995).
Hence, p120ctn does not directly modulate the actin cytoskeleton, implying a distinct role of
p120ctn in cadherin-catenin complex and downstream signaling.
p120ctn is thought to indirectly regulate assembly and disassembly of adherens junctions via
the Rho family of GTPases (Anastasiadis and Reynolds, 2000; Mariner et al., 2001; Anastasia‐
dis et al, 2000; Grosheva et al., 2001). p120ctn mediates cadherin-dependent activation of
RhoA at nascent cell-cell contacts, thereby regulating cadherin clustering and cell junction
formation (Anastasiadis et al., 2000). RhoA-GDP forms a complex with p120ctn in the cyto‐
plasm. Dissociation of GDP from RhoA is inhibited because of this trimer formation. In re‐
sponse to post-translational modification, such as tyrosine phosphorylation, p120ctn forms a
tighter complex with cadherin-catenin complexes at the cell membrane. The cadherin-bound
p120ctn dissociates from RhoA, resulting in the activation of RhoA by guanine nucleotide ex‐
change factors (GEFs) such as Vav2. The exchange of GDP for GTP activates RhoA, which
leads to downstream RhoA signaling events that promote cadherin clustering and junction
formation. Therefore, cytoplasmic p120ctn regulates specific signaling events at the cell mem‐
brane, but this does not preclude the role of nuclear p120ctn in signal transduction.
In response to a putative external signal, p120ctn translocates to the nucleus where it binds
Kaiso transcription factor, suggesting that p120ctn regulates transcriptional activity of un‐
identified target genes (Daniel and Reynolds, 1999; Van Hengel et al., 1999; Mariner et al.,
2000). Kaiso interacts with p120, but does not form a complex with E-cadherin, α−catenin or
β-catenin, suggesting a mutually exclusive interaction of p120ctn with either Kaiso or E-cad‐
herin. Kaiso is a DNA-binding protein that recognizes a specific consensus sequence and
methylated CpG dinucleotides (Daniel et al., 2002; Prokhortchouk et al., 2001). Kaiso is ubiq‐
uitously expressed in a panel of cell lines that includes human breast cancer cell lines MCF-7
and MDA-MB-231. However, human prostate cancer cell lines have not yet been character‐
ized with respect to Kaiso protein expression.
3.6. p120ctn isoforms
Most cell types express alternatively spliced isoforms of p120ctn (Anastasiadis and Reynolds,
2000; Thoreson and Reynolds, 2002; Staddon et al., 1995). The following nomenclature is
used to distinguish the multiple isoforms of p120ctn (Figure 4). Four different ATG start sites
at the N-terminal are used to generate p120 isoforms type 1, 2, 3 and 4. While all four iso‐
forms contain a central armadillo domain with ten arm repeats, only p120 isoform 1 contains
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a putative coiled-coil domain. The significance of this domain in tumorigenesis is not com‐
pletely understood. All p120ctn isoforms contain a loop in arm repeat 6, which is thought to
act as a nuclear localization signal. C-terminal splicing of p120ctn, where exons A, B, C or
none of the C-terminal exons are present adds to the complexity of p120ctn nomenclature. An
additional A, B or C designation is included in p120ctn nomenclatrure, based on which C-ter‐
minal exon is present. For example, p120ctn 1BC refers to an isoform of p120ctn that is spliced
at start site 1 in the N-terminus and contains exons B and C at the C-terminus. These four
p120ctn isoforms are differentially expressed based on cell type, suggesting that each isoform
may have a specific cellular function. For instance, macrophages and fibroblasts make N-
cadherin and express the p120ctn 1A isoform, whereas epithelial cells make E-cadherin and
express smaller isoforms such as p120ctn 3A (Anastasiadis and Reynolds, 2000). Based on al‐
ternative splicing, possible occurrence of up to 32 isoforms of p120ctn were found in human
cells (Anastasiadis and Reynolds, 2000). As discussed above, it is well established that
p120ctn interacts with E-cadherin, RhoA and the Kaiso transcription factor. However, the size
and specific isoform(s) involved in these interactions remains to be determined. Delineation
of the sub-cellular distribution (cytoplasmic vs nuclear) of p120ctn isoforms may provide
some insight into the specific function of each.
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Figure 4. Diagrammatic representations of the multiple isoforms of p120 catenin. Cell-type-specific alternative
splicing events result in multiple isoforms of p120 catenin. Four N-terminal ATG start sites generate p120 isoforms 1, 2,
3, and 4. p120 isoform 1 contains a putative coiled-coil domain (C-C), which is absent from isoforms 2-4. Additional
alternative splicing generates p120 isoforms using alternative exons in the C-terminal region, exons A, B and C. Iso‐
forms are designated p120ctn 1-4, depending on the N-terminal start site. The A, B, and/or C designations refer to the
exons present in the p120 catenin isoform. If none of the C-terminal exons are present, the letter N (for none) is used
in the nomenclature (e.g. p120ctn1N). PD, phosphorylation domain; NLS, Nuclear localization sequence.
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Similar to the situation with β and γ-catenin, increased levels of p120ctn in the cytoplasm
may direct translocation of p120ctn to the nucleus where a downstream signaling cascade is
initiated. Although the mechanism of nuclear translocation and the molecular basis for
p120ctn isoform specificity has not been described, post-translational modification of p120ctn
may be one means of directing p120ctn into either the cytoplasmic or the nuclear compart‐
ments. Specific sites of Src-initiated phosphorylation have been identified in murine p120,
isoform 1A (Mariner et al., 2001). All of the Src-stimulated phosphorylation sites are present
in the amino terminus of p120ctn, whereas the tyrosine residues in the armadillo repeat re‐
gions are not phosphorylated. Six of these phosphorylated sites cluster in a short-region up‐
stream of the first arm repeat and fourth ATG start site. The significance of Src
phosphorylation at these sites remains to be determined. Nonetheless, post-translational
modification of p120ctn may be involved in regulating cell-type specific expression patterns,
cellular distribution, and/or downstream signaling.
4. N-cadherin
N-cadherin is a member of the classical cadherin family of transmembrane glycoproteins in‐
volved in homotypic cell adhesion (Takeichi, 1995). The extracellular domain of N-cadherin
consists of five cadherin domains with residues that allow homophilic binding in the first ex‐
tracellular domain (ECD) (Shan et al., 1999; Koch et al., 1999).In neuronal cells, N-cadherin is in‐
volved in the control of axonal growth, synapse formation and synaptic plasticity (Matsunaga
et al., 1988; Riehl et al., 1996; Fannon and Colman, 1996; Inoue and Sanes, 1997; Tang et al., 1998;
Bozdagi et al., 2000). While it is known that N-cadherin is important in homotypic cell adhe‐
sion, there is some evidence that N-cadherin may also be involved in signaling cascades that
promote axonal growth (Utton et al., 2001). N-cadherin has been shown to have a role in bone
formation (Marie, 2002). In contrast to E-cadherin, which is primarily expressed on cells of epi‐
thelial origin, N-cadherin is expressed on mesenchymal cells, such as neuronal tissues, stromal
fibroblasts, muscle endothelium and in pleural mesothelial cells (Hazan et al., 1997b).
N-cadherin expression is also altered in pathological processes, such as metastasis of highly in‐
vasive cancer cells to regional lymph nodes and bone.The metastatic process is multifactorial,
with possible transition of cells from an epithelial to a mesenchymal phenotype promoting mi‐
gration of cells to distant sites. For example, breast cancer cell lines that have de-differentiated
(more primitive) to a mesenchymal phenotype have reduced expression of E-cadherin with
concomitant up-regulation of N-cadherin (Hazan et al., 1997b). The de-differentiated breast
cancer cells are capable of interacting with surrounding stromal tissues, supporting the inva‐
sive phenotype of the breast cancer cells. The epithelial to mesenchymal transition (EMT) is al‐
so seen in prostate cancer cell lines, and is correlated with the increased invasive capacity of
these cells (Tran et al., 1999). The more invasive prostate cancer cell lines (i.e., JCA-11) and pros‐
tate stromal fibroblasts express N-cadherin, with a loss of E-cadherin expression. This would
1 JCA-1 and TsuPr1 have now been identified as derivatives of T24 Bladder Carcinoma cells and are not of prostatic origin
(Van Bokhoven et al., 2001). However, JCA-1 and TsuPr1 remain relevant to our theoretical model of cancer cell invasion
due to their urogenital origin and therefore, are included in this thesis. JCA-1 and TsuPr1 are indicated with * to emphasize
the known origin of these cell lines.
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suggest that mutually exclusive expression of either E-cadherin or N-cadherin would establish
an epithelial or mesenchymal phenotype, respectively. Homotypic adhesion between prostate
cancer cells and stromal fibroblasts (encapsulating the prostate gland) could promote prostate
cancer cell invasion and extracapsular metastasis. The loss of E-cadherin and concomitant ex‐
pression of N-cadherin would allow prostate cancer cells to undergo an epithelial to mesenchy‐
mal transition allowing the cells to now become highly invasive.
5. Classical cadherins, Type II
5.1. Cadherin 11
Type II cadherins, cadherins 5, 6, 7, 8, 9, 10, 11, and 12, have structural features similar to Type I
cadherins, but differ in amino acid sequence. Type II mesenchymal cadherins are normally ex‐
pressed on stromal cells and osteoblasts. A mesenchymal cadherin, cadherin 11, and its truncat‐
ed variant are expressed on highly invasive breast cancer cell lines (Pishvaian et al., 1999), but
not on non-invasive cell lines. Previous studies have shown that cadherin 11 is expressed in em‐
bryonic mesenchymal tissues, and restricted to certain regions of neural tube (Kimura et al.,
1995; Hoffman and Balling, 1995). As tumor cells become more invasive and less differentiated,
with concomitant loss of E-cadherin expression, there is an increase in mesenchymal cadherin
expression. This pattern would suggest an epithelial to mesenchymal transition of highly inva‐
sive, poorly differentiated tumor cells. Although little is known about the expression pattern
and function of Type II cadherins in prostate cancer cell lines, expression of cadherin 11 may fa‐
cilitate metastasis of cancer cells and form distant lesions, particularly in the bone (Bussemakers
et al., 2000; Tomita et al., 2000). It is important to note that patients with advanced lung, breast or
prostate cancers develop bone metastasis (Mundy, 2002; Soos et al., 1997). In humans, prostate
cancer cells invade Batson’s vertebral veins, allowing metastatic cancer cells to reach and colo‐
nize distant sites within the bone (Geldof, 1997; Oesterling et al, 1997; Lehr and Pienta, 1998).
Therefore, successive E-cadherin down-regulation, expression of metalloproteinases, and ex‐
pression of mesenchymal cadherins allow prostate cancer cells to follow a defined metastatic
pathway. The prostate cancer cells may disassociate, invade the basement membrane, metasta‐
size, and colonize distant sites in the bone with concomitant expression of mesenchymal cadher‐
in 11. This type of cancer cell-stromal cell interaction mediated by cadherin 11 is seen in invasive
gastric cancers (Shibata et al., 1996). It is possible that E-cadherin acts as a tumor suppressor in
cancer progression, while cadherin 11 regulates invasion and formation of metastatic lesions in
the bone. This would warrant further investigation of the expression pattern and function of
cadherin 11, as well as its role in signalling metastatic progression of prostate cancer cell lines.
6. Matrix metalloproteinases
6.1. Structural motifs
The matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that
consist of more than 21 human MMPs. MMPs are divided into eight distinct structural
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groups, five of which are secreted and three of which are membrane-localized MMPs, MT-
MMPs (Table 1). The existence of multiple MMPs suggests that each MMP subfamily has a
specific function that is cell-type specific. Understanding the structural composition of each
of the MMP subfamilies may provide some insight into their differential expression and
function (Figure 5). MMPs contain an amino-terminal signal sequence (pre) that directs
them to the endoplasmic reticulum, a propeptide (pro) sequence with a zinc-interacting thiol
group that is cleaved upon activation, and a catalytic domain with a zinc-binding site. Clas‐
sification of MMPs into the eight subclasses is based on their structural motifs. For example,
Group 1 MMPs containing only the pre-, pro- and catalytic domains only, are called the
minimal-domain MMP (Sternlicht and Werb, 2001; Egelblad and Werb, 2002). Group 2
MMPs are simple hemopexin-domain containing MMPs with a hemopexin-like domain in
addition to the pre-, pro- and catalytic domains found in the minimal-domain MMPs. This
additional domain is involved in interactions with tissue inhibitors of metalloproteinases
(TIMPS), as well as with their proteolytic substrates. A hinge region connects the catalytic
and hemopexin domains. The function of the hinge region is not known, but molecular
modeling studies suggest that this region interacts with triple helical collagen (Nagase and
Woessner, 1999). Six of the eight structural groups contain the hemopexin domain with the
exception of Group 1, minimal- domain MMPs and Group 8, the Type II transmembrane
MMPs. While the specific mechanism of proteolytic cleavage is not known, the hemopexin
domain is essential for collagenases to cleave triple helical interstitial collagens (Bode, 1995).
Note, however, that MMPs have substrate specificity distinct from that of hemopexin do‐
main (Clark and Cawston, 1989). Cell-surface activation of pro-MMP2 requires the presence
of hemopexin-domain of MMP-2 (Murphy et al., 1992; Strongin et al., 1995). In addition, re‐
cent in vitro studies have suggested that the hemopexin domain may assist tumor cells in
evasion of immune surveilance. The hemopexin C-terminal domain of MT1-MMP has been
suggested to modulate the levels of complement component (gC1qR) in the tumor cell mi‐
croenvironment (Rozanov et al., 2002). C1q is a subcomponent of the C1 complex of the clas‐
sical pathway of complement activation. Active MT1-MMP can reduce the levels of soluble
gC1qR in the tumor vicinity via proteolytic cleavage. Interestingly, the hemopexin-like C-
terminal domain is involved in proteolytic cleavage of gC1qR. These in vitro studies imply
that tumor cells can evade immune surrveilance by hemopexin domain mediated cleavage
of complement components. Group 3 encompasses gelatin-binding MMPs containing fibro‐
nectin-like repeats that are associated with binding collagen (FI) and gelatin (Egeblad and
Werb, 2002; Allan et al., 1995; Steffensen et al., 1995). Groups 4-8 contain a motif between the
propeptide and catalytic domains that is recognized by intracellular furin-like serine protei‐
nases (FU). These MMPs are intracellularly activated by furin-initiated proteolytic cleavage
at this site. Groups 5 MMPs contain a vitronectin-like insert in addition to the FU recogni‐
tion motif. MMPs that are associated with the membrane include the membrane-type MMPs
(Group 6) and the glycosylphosphatidylinositol (GPI)-anchored MMPs (Group 7). Mem‐
brane-type MMPs (MT-MMPs) have a carboxy-terminal, single-span transmembrane do‐
main (TM) and a very short cytoplasmic domain (Cy). In contrast to the MT-MMPs, the GPI-
anchored MMPs are tethered to the membrane by a GPI component at the C-terminal.
Group 8 represents the type II transmembrane MMPs with an N-terminal signal anchor (SA)
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that targets the MMP to the cell membrane. MMP-23 is identified as a type II transmem‐
brane MMPs with unique cysteine array (CA) and immunoglobulin (Ig)-like domains at the
C-terminus. The functional significance of these domains has not yet been established.
MMP subfamily Structural Group MMP number MMP name Substrates
Collagenases 2 1 Interstitial collagenase Collagens I, II, III and VI, gelatins,
aggrecan, entactin
2 8 Neutrophil collagenase Collagens I, II, III, aggrecan
2 13 Collagenase-3 Collagens I, II, III
Gelatinases 3 2 72 kDa Type IV
gelatinase
Gelatin, collagens I, IV, V, VII, X, XI,
fibronectin, laminin, vitronectin
3 9 92 kDa Type IV
gelatinase
Gelatins, collagens IV, V, XIV,
aggrecan, elastin, entactin, vitronectin
Stromelysins 2 3 Stromelysin-1 Aggrecan, gelatins, fibronectin,
laminin, collagen III, IV, IX, X,
vitronectin
2 10 Stromelysin-2 Aggrecan, fibronectin, laminin,
collagen IV
4 11 Stromelysin-3 Fibronectin, laminin, collagen IV,
aggrecan, gelatins
2 18 Putative MMP Collagen I
Membrane-type MMPs 6 14 MT1-MMP Pro-MMP2, avb3 integrin, CD44,
proMMP13, fibronectin, laminin,
vitronectin, collagens I, II, III
6 15 MT2-MMP Not identified
6 16 MT3-MMP ProMMP-2
7 17 MT4-MMP Not identified
6 24 MT5-MMP Not identified
7 25 MT6-MMP Not identified
Other MMPs 1 7 Matrilysin (PUMP-1) Aggrecan, fibronectin, laminin,
collagen IV, elastin, entactin,
vitronectin
2 12 Macrophage elastase Elastin
2 19 Rheumatoid arthritis-
associated MMP
Not identified
2 20 Enamelysin Amelogenin
5 21 Homologue of Xenopus
XMMP
2 22 CMMP
8 23 Cysteine array MMP
1 26 Endometase,
matrilysin-2
Fibronectin, vitronectin, fibrinogen,
type IV collagen, MMP9, gelatin
2 27 Unkown
4 28 Epilysin
Table 1. Classification and Nomenclature of Human MMPs. MMP superfamily is classified into eight structural groups.
While five of these groups are secreted, three groups are membrane-bound. The MMP subfamily, structural group
number, corresponding MMP number and the common name are shown in the table. Substrates for each enzyme are
also listed in the table (Vincenti, 2000; Nagase and Woessner, 1999; Egelblad and Werb, 2002). MMP Structural
Groups: Group 1, Minimal-domain; Group 2, Simple hemopexin-domain-containing; Group 3, Gelatin-binding; Group
4, Furin-activated secreted; Group 5, Vitronectin-like insert; Group 6, Transmembrane; Group 7, GPI-anchored; Group
8, Type II Transmembrane.
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Signal peptide (pre) 
Propeptide 
domain (pro) 
Catalytic 
domain 
Hinge 
region 
C-terminal ‘heamopexin-
like’ domain 
Fibronectin-like insertion 
Collagenases and stromelysins 
Gelatinases 
Membrane-type MMPs 
Transmembrane domain 
Figure 5. Structure of the matrix metalloproteinase. MMPs contain the following domains: signal peptide (pre-pep‐
tide), propeptide, catalytic domain, hinge region, and hemopexin-like domain. The cleavage of N-terminal propeptide
domain of the latent MMP yields the active form of the enzyme. The gelatinases contain a fibronectin-like region with‐
in their catalytic domain. The membrane-type MMPs are characterised by a C-terminal transmembrane domain. The
hemopexin-like repeat is absent in matrilysin (MMP-7).
Common names  are  also  used to  distinguish  substrate  specificity  for  each  of  the  MMP
groups described above. For example, interstitial collagenases, such as MMP-1 (structural
group 2), have high specificity for fibrillar collagen types I, II, and III. In contrast, gelati‐
nases, MMP-2 and MMP-9 (structural group 3), have a greater propensity to cleave dena‐
tured  collagen  products,  as  well  as  basement  membrane  components  such  as  collagen
type  IV.  Stromelysins,  such  as  MMP-3  (structural  group 2),  cleave  extracellular  compo‐
nents  and have the ability  to activate other MMPs.  Recently,  a  new subfamily of  mem‐
brane-tethered or membrane-type MMPs, MT-MMPs (Group 6) has been included in the
MMP family. Five enzymes: MT1-, MT2-, MT3-, MT4- and MT5- (Sato et al., 1996; Takino
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et al., 1995; Will and Hinzmann, 1995; Puente et al., 1996; Pei, 1999) have been identified
as members of this group.
MMPs are synthesized as inactive zymogen requiring proteolytic cleavage of the N-termi‐
nus in order to be activated. A cysteine-sulphydryl group in the propeptide domain inter‐
acts with a zinc ion bound to the catalytic domain. Proteolytic cleavage removes the
propeptide domain, leading to the activation of latent MMP (Cao et al., 1998). Generally,
MMPs are activated by either serine proteinases or other activated MMPs outside of the cell.
In contrast, MMP-11, MMP-28 and MT-MMPs are activated by intracellular furin-like serine
proteinases before they are associated with the cell membrane. MMP activity is regulated at
three levels: transcription, activation, and inhibition/deactivation.
6.2. Transcriptional regulation of MMPs
Increased MMP expression in tumors is primarily associated with transcriptional changes
rather than genetic alterations, although translocation of MMP23 genes in neuroblastoma
and amplification of MMP24 gene have been reported (Llano, 1999). Transcriptional regula‐
tion of MMP mRNA expression is subject to influences by several chemical reagents, neuro‐
hormones, and cytokines (Liotta et al., 1983; Unemori and Werb, 1988; Galis et al., 1994;
Werb et al., 1989; Matrisian and Hogan, 1990). For example, tumor necrosis factor alpha
(TNF-α) and interleukin-1 can stimulate the production of MMP-1, MMP-3, and MMP-9
(MacNaul et al., 1990). While the pathways by which these factors regulate MMP transcrip‐
tion remain to be determined, it is known that the MMP promoter regions contain response
elements that transcriptionally regulate expression. Tumor response element (TRE) and acti‐
vation protein-1 (AP-1) binding sites are present in MMP-1, MMP-3, MMP-7, MMP-9,
MMP-10, MMP-12 and MMP-13 (Benbow and Brinkerhoff, 1997). Transcriptional regulation
can be further influenced either by genetic polymorphisms or by growth factor-activated
transcription factors. MMP-1 protein expression is influenced by polymorphisms in MMP-1
gene promoter. Promoters of inducible MMPs and TIMPs have specific sites that bind AP-1
and Polyoma Enhancer A-binding Protein-3 (PEA-3), which is pivotal in transcriptional acti‐
vation. While Fos and Jun families of transcription factors bind to AP-1 sites, PEA-3 binds to
the Ets binding sites (EBS). The presence of two guanine nucleotides in the MMP-1 promoter
creates a functional Ets-binding site adjacent to an AP-1 site, up-regulating the transcription
of MMP-1 gene in multiple cancers, including ovarian cancers (Kanamori, 1999). MMP tran‐
scription can also be downregulated in response to certain signals. For example, MMP-1
transcription can be repressed in the presence of the tumor suppressor p53 (Sun et al., 1999).
Interestingly, p53 is also known to differentially regulate MMP-13 expression (Sun et al.,
2000). Another example of transcriptional regulation of MMPs is the up-regulation of
MMP-7 expression in colon tumors (Crawford, 2001). The PEA-3 subfamily of Ets transcrip‐
tion factors and the β-catenin-LEF-1 complex activate MMP-7 expression in colon tumors.
These findings suggest that multiple regulatory elements in MMP promoter regions coor‐
dinately regulate tissue-specific and temporal expression of MMP.
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6.3. Activation of MMPs
While transcriptional regulation is important in determining MMP synthesis, activation of
MMPs is a key factor in regulating proteolysis of specific substrates. Newly synthesized
MMPs are secreted into the extracellular space in zymogen form. Outside the cell, other
MMPs, serine proteinases, growth factors, and chemical/physical reagents can activate the
latent MMP. Proteolytic enzymes such as urokinase, plasmin, and cathepsins are known to
activate MMPs. In addition, organomercurials (APMA) are used routinely to activate MMPs
under experimental conditions. MMP activity in vivo has been associated with the interstitial
form urokinase plasminogen activator (uPA). Recent evidence has shown that latent MMP-2
is activated at the cell surface in a highly regulated pathway involving tissue inhibitors of
metalloproteinases-2 (TIMP-2) and MT1-MMP (Hernandez-Barrantes et al., 2000). TIMP-2
binds MT1-MMP at its N-terminus and proMMP-2 at its C-terminus. Another free MT1-
MMP molecule cleaves the bound proMMP-2, leading to partial activation of MMP-2. An‐
other fully activated MMP-2 is required to remove a residual portion of the MMP-2
propeptide (Deryugina, 2001). At low concentrations, TIMP-2 stimulates proMMP-2 activa‐
tion; at high concentrations, it inhibits MMP-2 activation.
6.4. Inhibition of MMP activity
Inhibition/deactivation of MMPs can be accomplished by several factors including α-2-mac‐
roglobulin, tissue inhibitors of metalloproteinases (TIMPs), small molecules with TIMP-like
domains, and the membrane-bound inhibitor RECK (reversion-inducing cysteine-rich pro‐
tein with kazal motifs) (Sasahara et al., 2002). In tissue fluids, α2-macroglobulin forms a
complex with MMPs that can bind to a scavenger receptor. Endocytosis removes the trimer‐
ic complex, α2-macroglobulin-MMP-scavenger receptor, in an irreversible manner. The ac‐
tivity of MMPs is regulated by the presence of endogenous protein inhibitors, Tissue
Inhibitors of Metalloproteinases (TIMP). Four TIMPs (TIMPs1-4) have been identified, each
with a specific function (Gomez et al., 1997). TIMPs inhibit tumorigenesis, cell invasion,
metastasis and angiogenesis. A fine balance between MMPs and TIMPs regulates tumor
progression. TIMP binds to the active site of MMP, leading to a conformational change in
the enzyme. The ratio of MMP to its specific TIMP determines the metastatic potential of a
tumor cell. Recent evidence suggests that an increase in MMP2 to TIMP2 ratio is associated
with high-grade and high-stage prostate tumors (Still et al., 2000).
6.5. Normal and pathological processes involving MMP expression
MMPs are involved in normal embryonic development (Alexander et al., 1996b; Lelongt et
al., 1997), renal organogenesis (Lelongt et al., 1997), and invasion and metastasis of cancer
(Stetler-Stevenson et al., 1993). There are several examples of normal embryonic develop‐
ment that require MMP expression, including trophoblast implantation, embryonic growth,
and tissue morphogenesis. In addition, MMPs are required for normal wound repair. As
part of the wound repair process, development of new tissue at the site of injury involves a
series of highly regulated events. MMPs degrade several components of the extracellular
matrix (ECM), followed by migration of new cells to the site leading to formation of new
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ECM at the injured site. The level as well as the tissue-specificity of MMPs can determine
the degree of wound repair. For example, MMP-7 is the only MMP expressed by lung epi‐
thelial cells under conditions of tracheal damage (Dunsmore et al., 1998). In contrast, more
than one MMP is required for epithelial cell migration during normal wound repair (Sud‐
beck et al., 1997). While different levels of MMP-1, -2, and –9 have been detected at the
wound site, neutrophil-derived MMP-8 is the primary collagenase present in normal healing
wounds. However, unregulated expression of MMP-8 is associated with chronic leg ulcers
(Armstrong and Jude, 2002; Nwomeh et al., 1999). Mammary gland development and invo‐
lution is another example of a physiological process that requires tightly regulated expres‐
sion of MMPs (Lund et al., 1996). In summary, regulation of MMP expression and MMP
activity is essential for normal cellular processes.
Pathological processes that are associated with aberrant MMP expression include cardio‐
vascular disease (Libby, 1995;  Thompson et al.,  1995),  interstitial  fibrosis (Norman et al.,
1995), glomerulosclerosis (Schaefer et al., 1997; Jacot et al., 1996), pulmonary emphysema
(D’Armiento et al., 1992), and bullous pemphigoid (Liu et al., 1998), an autoimmune sub-
epidermal blistering disease. MMPs are also associated with tumor progression and con‐
tribute  to  tumor  invasion  and  metastasis.  MMPs  are  associated  with  five  principal
processes promoting tumor progression (Egeblad and Werb, 2002). First, MMPs can pro‐
mote cancer cell proliferation by three known mechanisms. These include release of cell-
membrane-bound precursors of some growth factors, such as TGF-α, degradation of ECM
proteins resulting in the release of peptide growth factors, or indirect proliferative signals
through integrins. Second, MMPs regulate apoptosis as well as anti-apoptosis. MMP-3, -7,
-9 and –11 are known to regulate apoptosis involving different signaling processes. Over‐
expression of  MMP-3 is  known to induce apoptosis  in  mammary epithelial  cells  by de‐
grading  laminin  (Alexander  et  al.,  1996a;  Witty  et  al.,  1995)  and  MMP-7  cleaves  FAS
ligand, a ligand for the death receptor FAS, from its membrane-bound precursor. As a re‐
sult of this cleavage, a pro-apoptotic molecule is released into the surrounding microen‐
vironment (Powell et al., 1999; Mitsiades et al., 2001). MMPs can also induce apoptosis of
endothelial cells or epithelial cells by shedding the adhesion molecules VE-cadherin (Her‐
ren  et  al.,  1998),  PECAM-1  (Ilan  et  al.,  2001)  and  E-cadherin  (Steinhusen  et  al.,  2001).
Third, MMPs are positive regulators of angiogenesis, which is required for tumor growth.
MMP-2, -9 and –14 and –19 have been shown to regulate angiogenesis by promoting the
availability of factors involved in angiogenesis, such as vascular endothelial growth factor
(VEGF), fibroblast growth factor 2 (FGF-2) and TGF-β. These factors are required for en‐
dothelial  cell  proliferation and migration. Moreover,  MMP-2 is required for transition to
an angiogenic phenotype in a tumor model (Fang et al., 2000), suggesting that MMPs are
important for maintenance of tumor growth and proliferation. Fourth, MMPs allow cancer
cells to evade immune surveillance. For example, MMP-9 can cleave interleukin-2 recep‐
tor-a (IL-2Ra) from the surface of activated T lymphocytes, thereby suppressing their pro‐
liferation (Sheu et al., 2001). As a result of this suppression, tumor-specific T lymphocytes
cannot infiltrate tumor cells. MMP-11 also generates a cleavage product that allows tumor
cells to evade the tumor-targeted activity of natural killer cells. MMP-11 cleaves α1-protei‐
nase-inhibitor, which decreases natural killer cell cytotoxicity (Kataoka et al., 1999). Active
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membrane-type 1 MMP (MT1-MMP) has also been suggested to assist tumor cells in eva‐
sion of immune surveillance (Rozanov et al., 2002). Therefore, tumor cells escape immune
surveillance leading to uncontrolled tumor growth. Fifth, MMPs degrade extracellular ma‐
trix components and allow tumor cells to migrate across epithelial basement membranes
and metastasize to a new site. While the exact mechanism triggering MMP release by tu‐
mor cells  is  not  yet  completely understood,  MMPs are the only enzymes known to de‐
grade fibrillar collagen types I, II, III and IV. MMP-2, -3, -13 and –14 promote invasion of
cell lines in in vitro models of invasion (Lochter et al., 1997; Belien et al., 1999; Deryugina
et al., 1997; Polette and Birembaut, 1998). Furthermore, MMP-2 and MMP-14 cleave lami‐
nin-5 leading to cell motility (Koshikawa et al., 2000). Proteolytic cleavage of CD44 as well
as integrin αv subunit by MMP-14 promotes cell migration (Kajita et al., 2001; Deryugina,
2001).  Recently,  MT-MMP1 has been identified as a downstream target of the β-catenin/
Tcf4 complex in colorectal cancers, suggesting that E-cadherin-catenin signaling is impor‐
tant  in  regulating  MT-MMP1 expression  (Takahashi  et  al.,  2002).  Interestingly,  MMP-14
has recently been shown to function as  an integrin convertase promoting cell  adhesion,
migration and focal  adhesion kinase phosphorylation of  breast  cancer  cells  (Ratnikov et
al., 2002). These findings suggest that MMP-14 may be important in regulating cross-talk
between integrin and cell-adhesion molecules. MMP-3 as well as MMP-7 cleaves E-cadher‐
in leading to tumor progression (Noe et al.,  2001).  The newly released E-cadherin cleav‐
age product  could interfere with another unprocessed E-cadherin molecule such that  E-
cadherin function is impaired and, as a result, tumor-cell invasion ensues. Taken together,
MMPs are important in many aspects of tumor progression in addition to tumor cell mi‐
gration and invasion.
6.6. Role of MMP in prostate cancer
Growth factors and receptor kinases can also influence transcriptional regulation of MMPs.
MMPs have been shown to play a significant role in prostate cancer metastasis (Wood et al.,
1997; Sehgal et al, 1998; Pajouh et al, 1991; Powell et al, 1993). Moreover, recent evidence
suggests an increase in MMP-2 and TIMP-2 ratio is associated with high-grade and high-
stage prostate tumors (Still et al., 2000). MMP expression could be induced by two possible
mechanisms. First, prostate stromal cells could secrete growth factors such as epidermal
growth factor (EGF) and induce expression of downstream effectors such as metalloprotei‐
nases. Growth factors and their receptors have been shown to be key components of tumor
development and progression (Sundareshan et al., 1999). Epidermal growth factor receptor
(EGFR) expression in bladder cancer cells, for example, is associated with high tumor stage
and grade (Nutt et al., 1998). EGF has been shown to induce the AP-1 transcriptional regula‐
tory complex, which transcriptionally activates MMP-1 expression and MMP-3 expression
in fibroblasts. EGFR stimulation promotes both breast cancer cell migration (Price et al.,
1999) and induces MMP-1 expresssion (Nutt and Lunec, 1996). Second, MMP expression is
also regulated by E-cadherin expression (Nawrocki-Raby et al., 2003). Restoration of E-cad‐
herin expression in E-cadherin negative Dunning rat prostate tumor cells inhibits in vitro
invasion and MMP-2 activity in these cells (Luo et al., 1999).
The Role of E-Cadherin-Catenin Complex in Prostate Cancer Progression
http://dx.doi.org/10.5772/52751
663
7. Concluding remarks
The cellular localization of E-cadherin and the catenin proteins has a significant role in regu‐
lating cancer progression. β-, γ- and p120ctn proteins are important components of the E-cad‐
herin-catenin signal transduction pathway. Elucidating the mechanisms of nuclear
localization or nuclear retention of β-, γ- and p120ctn proteins, may help us to understand the
role of these catenins in regulating E-cadherin downstream signaling events associated with
prostate cancer invasion.
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